02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
22:08 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Nimble move

Celgene Corp.’s deal with Nimbus Therapeutics LLC is another vote of confidence that Nimbus’ computational drug design technology can solve druggability problems that trip up standard medicinal chemistry. The partnership gives Celgene access to two...
03:39 , Apr 22, 2017 |  BioCentury  |  Product Development

Playing JAKs

A desire to improve upon marketed autoimmune drug Xeljanz tofacitinib, coupled with interesting biological findings, led Pfizer Inc. to develop a portfolio of selective Janus kinase inhibitors that are taking the target into new disease...
19:14 , Jan 26, 2017 |  BC Innovations  |  Translation in Brief

Blanketly blocking MLL

Seven years after it discovered the unifying factor underlying the 70 seemingly unrelated translocations that all lead to mixed-lineage leukemia (MLL), a Northwestern team has devised a therapeutic strategy that could work across virtually all...
19:14 , Jan 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Leukemia Cell culture and mouse studies suggest inhibiting IRAK4 could help treat mixed-lineage leukemia (MLL). In HEK cells, shRNA targeting IRAK4 or an IRAK4 inhibitor tool compound increased the stability of wild-type MLL1, but not...
07:00 , Oct 6, 2016 |  BC Innovations  |  Targets & Mechanisms

Seeking cysteines

In settling the question of how Biogen Inc.'s Tecfidera dimethyl fumarate (DMF) acts in multiple sclerosis, a Scripps team has identified PKCθ as a key driver, sitting atop an NF-κB pathway to immunosuppression. The results...
00:33 , Apr 5, 2016 |  BC Extra  |  Top Story

Gilead acquiring Nimbus' NASH subsidiary

Gilead Sciences Inc. (NASDAQ:GILD) is acquiring the Nimbus Apollo Inc. subsidiary of Nimbus Therapeutics LLC (Cambridge, Mass.) for $400 million up front and up to $800 million in development milestones. The deal gives Gilead a...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

Nimbus Therapeutics, Roche, Genentech deal

Nimbus granted Roche’s Genentech unit exclusive, worldwide rights to develop and commercialize small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4). The partners declined to name specific programs or indications the partners will study,...
00:57 , Oct 21, 2015 |  BC Extra  |  Company News

Genentech licenses IRAK4 inhibitors from Nimbus

Computational chemistry company Nimbus Therapeutics LLC (Cambridge, Mass.) granted the Genentech unit of Roche (SIX:ROG; OTCQX:RHHBY) an exclusive, worldwide license to develop and commercialize small molecule inhibitors of interleukin-1 receptor-associated kinase 4 ( IRAK4). Neither...